Infosys shares fell nearly 6% on Friday, marking their largest one-day decline since July 2023. The drop followed concerns raised by analysts over the quality of earnings in its third-quarter report. By 11:49 a.m. IST, Infosys shares were down 5.7%, weighing heavily on both the Nifty IT index and the benchmark Nifty 50, which declined 2.5% and 0.7%, respectively. Its U.S.-listed shares also dipped about 6% overnight.
The company raised its annual revenue forecast for the third time this financial year, driven by increased spending from U.S. banking and retail clients on discretionary projects. This mirrors trends seen in competitors Tata Consultancy Services and HCLTech. Despite the optimistic outlook, analysts expressed concerns about the reliance on "third-party items" in Infosys' deal pipeline, which cast doubts on the quality of the reported earnings beat.
Morgan Stanley noted that commentary around small deal pipelines showed no significant improvement, suggesting a gradual industry recovery. Small deals account for over two-thirds of Infosys' total deal intake, according to BofA Global Research. Markets now seek concrete signs of increased discretionary spending rather than optimistic commentary from IT firms.
Infosys shares have risen 22.5% in 2024, outperforming Tata Consultancy Services and LTIMindtree, but trailing HCLTech, which gained 31%. The earnings report, while positive on paper, has sparked debate on whether revenue growth is sustainable, given the current market dynamics.


Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
U.S. Condemns China's Dominance in Global Shipbuilding and Maritime Sectors
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Gold Prices Rise as Markets Await Trump’s Policy Announcements
Apple Downgraded by Jefferies Amid Weak iPhone Sales and AI Concerns
China's Refining Industry Faces Major Shakeup Amid Challenges
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Investors value green labels — but not always for the right reasons
China’s Growth Faces Structural Challenges Amid Doubts Over Data
Mexico's Undervalued Equity Market Offers Long-Term Investment Potential
U.S. Stock Futures Rise as Trump Takes Office, Corporate Earnings Awaited
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Tempus AI Stock Soars 18% After Pelosi's Investment Disclosure
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 



